Patents Examined by Merrell C. Cashion, Jr.
  • Atrial natriuretic peptide derivative
    Patent number: 5159061
    Abstract: A peptide derivative of the formula ##STR1## wherein A is hydrogen or a hydrocarbon acyl having 2 to 18 carbon atoms which is substituted by an amino group at the .alpha.-position; B is F-Gly wherein F is a neutral .alpha.-amino acid residue, or NH-(CH.sub.2)nCO wherein n is an integer of 1 to 4; C is a neutral .alpha.-amino acid residue; and E is L-Arg or D-Arg; when A, B and C are hydrogen, Gly-Gly, and Met or Ile, respectively, E is D-Arg, or its pharmacologically acceptable salt has strong hypotensive and natriuretic activity; therefore it is useful as a therapeutic drug for hypertension, a diuretic, and a therapeutic drug for cardiac and cerebral circulatory diseases.
    Type: Grant
    Filed: September 25, 1987
    Date of Patent: October 27, 1992
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Masahiko Fujino, Mitsuhiro Wakimasu, Kohei Nishikawa
  • Trichothecene conjugates
    Patent number: 5157104
    Abstract: Conjugates of trichothecenes and agents that bind to a defined population of cells are disclosed. Preferred are conjugates of trichothecene molecules with polyclonal or monoclonal antibodies or fragments thereof that recognize antigens that are present only on tumor cells or are augmented in their expression on tumor cells as compared to normal tissues. Trichothecene molecules are coupled to the agent through non-covalent and covalent linkages, such as peptide bonds, disulfide bonds, thioester bonds, or thioether bonds. A method for inhibiting the growth and metabolism of antigen-positive cells is also disclosed.
    Type: Grant
    Filed: May 16, 1988
    Date of Patent: October 20, 1992
    Assignee: NeoRx Corporation
    Inventors: Gowsala Sivam, Paul G. Abrams
  • Method of bonding collagen to fibers, particularly dacron
    Patent number: 5157111
    Abstract: A method of bonding collagen to synthetic polyester fibers, particularly DACRON. The method involves providing synthetic polyester fabric fibers having repeating carbonyl groups, hydrogenating the repeating carbonyl groups and then conducting a transesterification step which includes the addition of free amine groups. The free amine groups are reacted with a bifunctional crosslinking agent to produce modified polyester fibers. The final step involves adding collagen to the modified polyester fibers for a time sufficient to produce covalent bonding of the collagen to the fibers.The invention also involves the making of a fabric matrix comprised of synthetic polyester fibers, particularly DACRON, and collagen being covalently bound to the fibers. Such matrix can be utilized in ligament prosthesis design.
    Type: Grant
    Filed: May 2, 1991
    Date of Patent: October 20, 1992
    Inventor: James M. Pachence
  • Removal of nucleic acids from monoclonal antibody preparations
    Patent number: 5157113
    Abstract: An essentially pure and stablized antibody preparation comprising IgM antibodies having a purity greater than about 98% by weight and a nucleic acid content of less than about 200 pg per mg IgM. In one embodiment IgM antibodies from a monoclonal source are subjected to ion exchange and size exclusion chromatography at an alkaline pH to yield a purified IgM having a nucleic acid content of less than 10 pg/mg IgM, preferably less than about 4 pg/mg IgM. A highly purified and stabilized preparation of anti Pseudomonas aeruginosa antibodies is disclosed. The removal of nucleic acids is assured by subjecting the antibody source to at least one and preferably two low pH precipitation steps. In a very preferred embodiment, ion exchange and/or size exclusion chromatography is used to remove any residual nucleic acids.
    Type: Grant
    Filed: April 12, 1991
    Date of Patent: October 20, 1992
    Assignee: Miles Inc.
    Inventors: George Dove, Gautam Mitra
  • Process for reducing the salt concentration in a biomass suspension
    Patent number: 5155040
    Abstract: Alcohol is suitable for the extraction of salt from biomass-containing suspensions, in particular from the salt-containing lower phase of an aqueous 2-phase extraction of intracellular proteins after cell disruption, with the formation of a salt-containing alcoholic upper phase. It is possible to use ethanol, propanol, isopropanol or tert.-butanol, but especially ethanol, as the alcohol. The upper phase is separated from the lower phase by disk separators or decanters. The extraction is carried out, in particular, as a countercurrent extraction in at least three stages, and uses 10 to 30% by weight salt-containing suspension or liquid with 30 to 50% by weight alcohol, in particular ethanol, remainder water. The alcohol is removed from the resulting salt-rich upper phase by evaporation, and the salt solution is recycled where appropriate after further concentration to obtain proteins.
    Type: Grant
    Filed: March 15, 1990
    Date of Patent: October 13, 1992
    Assignee: Forschungszentrum Juelich GmbH
    Inventors: Maria-Regina Kula, Arend Greve
  • Tripeptide derivatives and protease inhibitor composition comprising the same
    Patent number: 5153176
    Abstract: Tripeptide derivatives of formula (I) such as N-.epsilon.-(p-tosyl)-D-lysyl-L-prolyl-L-argininal have an activity of inhibiting a plurality of trypsin-like serine proteases, e.g., plasmin, thrombin, trypsin, kallikrein, factor Xa, urokinase, etc. in vivo. The tripeptide derivatives can be expected as novel protease inhibitors due to their remarkable pharmaceutical effects.
    Type: Grant
    Filed: July 30, 1991
    Date of Patent: October 6, 1992
    Assignee: Nitto Boseki Co., Ltd.
    Inventors: Yoshihito Abe, Takeshi Nagasawa, Katsumasa Kuroiwa, Katsuhiro Yaginuma
  • Process for incorporating a material in a crosslinked gelatin, and product therefrom
    Patent number: 5153177
    Abstract: A method of crosslinking protein comprises making a composition which comprises a protein, a sugar, a water-soluble salt of a carboxylic acid, water, and an additional ingredient which is to be encapsulated or entrapped within the crosslinked protein matrix. The composition is thereafter heated while maintaining the moisture content at a level of at least about 3 weight percent, based on the weight of the composition.A product comprises a protein which is crosslinked to degree at which it is substantially insoluble upon being placed in water at 100.degree. C. for at least 3 minutes, a sugar, a water-soluble salt of a carboxylic acid, water, and an additional ingredient which is encapsulated or entrapped within the crosslinked protein matrix.
    Type: Grant
    Filed: January 10, 1991
    Date of Patent: October 6, 1992
    Assignee: BASF Corporation
    Inventors: Frederick K. Chaundy, David K. Bower, Terence K. Kilbride, Jr.
  • Process of making tetrahydropteroylpoly-L-glutamic acid derivatives
    Patent number: 5153309
    Abstract: The invention is a method of synthesizing tetrahydropteroylpoly-L-glutamic acid derivatives starting from the mono-L-glutamic acid derivatives. The method has the advantage of not requiring any enzymes.
    Type: Grant
    Filed: July 27, 1990
    Date of Patent: October 6, 1992
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventor: Anthony L. Fitzhugh
  • Polymer mixtures useful in skin care
    Patent number: 5153174
    Abstract: Binary polymer mixtures of albumin and glycosaminoglycan and ternary polymer mixtures of polyionic polypeptide and high molecular weight and highly charged polyanions are useful for managing skin including wrinkles or other irregularities. Aqueous compositions of the ternary mixtures have pH dependent phase change properties and provide skin activated films.
    Type: Grant
    Filed: October 30, 1989
    Date of Patent: October 6, 1992
    Assignees: Union Carbide Chemicals & Plastics Inc., Biomatrix Incorporated
    Inventors: Philip A. Band, Arminda G. Barbone, Errol D. Goddard, Adolf Leshchiner, Emmett M. Partain, III, Joseph P. Pavlichko
  • Method for purification of monoclonal antibodies
    Patent number: 5151504
    Abstract: An improved method for the purification of monoclonal antibodies using Protein G, whereby the monoclonal antibodies are eluted from the Protein G at alkaline pH.
    Type: Grant
    Filed: March 26, 1990
    Date of Patent: September 29, 1992
    Assignee: E. R. Squibb & Sons, Inc.
    Inventor: Edward M. Croze
  • Method for solubilizing membrane receptor proteins
    Patent number: 5151502
    Abstract: A process for solubilizing membrane receptor proteins which includes exposing an outer membrane having the desired protein to an oxidizing agent, treating the membrane with a detergent and treating with an inhibitory material lowering agent. This method maintains the activity of the membrane proteins after solubilization.
    Type: Grant
    Filed: April 30, 1991
    Date of Patent: September 29, 1992
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Maria L. Webb, Hossain Monshizadegan
  • Process for reducing hydrolysed protein chlorohydrin content
    Patent number: 5151503
    Abstract: The chlorohydrin content of a liquid containing hydrolyzed protein obtained by hydrolysis of protein with hydrochloric acid is reduced in an apparatus system by introducing alkali into the liquid flowing under pressure in a piping system to increase the pH of the liquid, after which the pH-increased flowing liquid is heated, and then the heated flowing liquid is held for a time sufficient in a holding piping section to reduce the chlorohydrin content of the hydrolyzed protein contained in the liquid. The flowing liquid under pressure then is cooled before or after addition of hydrochloric acid which is employed to adjust the pH of the liquid.
    Type: Grant
    Filed: March 28, 1991
    Date of Patent: September 29, 1992
    Assignee: Nestec S.A.
    Inventors: Roland Fasi, Milo A. Nielsen
  • Immunopotentiating protocol for chemotherapy-responsive tumors
    Patent number: 5149527
    Abstract: Immunopotentiating compositions which are useful in causing tumor necrosis and/or regression in subjects who have previously received successful therapy which destroys tumors and stimulates cytotoxic macrophages are described. The immunopotentiators are administered at a time when formation of macrophages specifically cytotoxic for the tumor have been generated by previous therapy.
    Type: Grant
    Filed: September 18, 1990
    Date of Patent: September 22, 1992
    Assignee: Oncotech, Inc.
    Inventor: Larry M. Weisenthal
  • Method of using cold-adapted live influenza virus vaccine as an antiviral agent against influenza
    Patent number: 5149531
    Abstract: A method of treating a patient for having influenza includes introducing intranasally into said patient a prophylactically or therapeutically effective dosage of an attenuated reassortant live influenza virus as an antiviral agent and effecting by said introduction immediate interference with the growth of said influenza virus.
    Type: Grant
    Filed: June 27, 1990
    Date of Patent: September 22, 1992
    Assignee: University of Pittsburgh of the Commonwealth System of Higher Education
    Inventors: Julius S. Youngner, Patricia W. Dowling
  • Assay for total and direct billirubin
    Patent number: 5149272
    Abstract: Novel reagent compositions and an assay method for the measurement of total and direct bilirubin are disclosed. The reagent compositions comprise an aqueous solution of at least one betaine selected from the group of alkyl betaine, betaine and betaine hydrate, a sulfanilamide diazonium salt, iodide ions and sulfamic acid. In the measurement of total bilirubin, alkyl betaine serves as an accelerator/solubilizer for the reaction of unconjugated bilirubin, and the alkyl betaine, betaine or betaine hydrate, together with iodide ions, minimizes or substantially eliminates interference from hemoglobin and lipemia.
    Type: Grant
    Filed: May 30, 1991
    Date of Patent: September 22, 1992
    Assignee: Boehringer Mannheim Corporation
    Inventors: Yih-Shiong Wu, Jeanne Bohannon, Yolanda White, Mark J. Simmons
  • Human insulin analogs and preparations containing them
    Patent number: 5149777
    Abstract: Novel human insulin analogs exhibiting high biological activity and in which the amino acid residue Phe.sup.B25 is substituted by His or Tyr and moreover substitutions may optionally be present in one or more of the positions A4, A8, A17, A21, B9, B10, B12, B13, B21, B26, B27, B28, and B30, as well as the amino acid residue in the B30 position may further be totally missing or may be blocked at the C-terminal in the form of ester or amide.
    Type: Grant
    Filed: March 19, 1991
    Date of Patent: September 22, 1992
    Assignee: Novo Nordisk A/S
    Inventors: Finn B. Hansen, Per Balschmidt
  • Insulin derivatives, process for their preparation, their use and a pharmaceutical preparation containing them
    Patent number: 5149716
    Abstract: The invention relates to insulin derivatives of the formula III ##STR1## in which R.sup.30 and R.sup.31 together are OH, or R.sup.30 is a radical of a neutral, genetically encodable L-amino acid and R.sup.31 is OH or a physiologically acceptable organic group of basic character having up to 50 carbon atoms, whose synthesis involves 0 to 3 .alpha.-amino acids and whose optional terminal carboxyl function can be present free, as an ester function, as an amide function, as a lactone or reduced to CH.sub.2 OH, and R.sup.A-1 is a radical of a genetically encodable L-amino acid, and physiologically acceptable salts of said insulin derivative of the formula III.
    Type: Grant
    Filed: October 26, 1990
    Date of Patent: September 22, 1992
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Laszlo Vertesy, Karl Geisen, Richard Bicker
  • Aluminum deposited film and process for producing it
    Patent number: 5147726
    Abstract: The present invention relates to an aluminum deposited film and a process for producing it. Since the surface area coefficient C of the surface of the deposited layer is not greater than 1.00.times.10.sup.-4 or aluminum crystals the [1, 1, 0] planes of which are oriented in parallel with the surface of a base film are contained in an aluminum thin layer in an aluminum deposited film. The corrosion resistance in a high-temperature and high-humidity atomsphere of the aluminum deposited film is excellent. A capacitor coated with the aluminum deposited film has excellent moisture resistance even if its encapsulation is simple, or has increased moisture resistance when its encapsulation is constructed as one similar to that of a conventional capacitor.
    Type: Grant
    Filed: May 24, 1990
    Date of Patent: September 15, 1992
    Assignee: Toray Industries, Inc.
    Inventors: Motoyuki Suzuki, Yukichi Deguchi
  • Process for treatment of diseases
    Patent number: 5145677
    Abstract: This invention relates to the treatment of various diseases such as such as those characterized by tumorigenic or neoplastic cell growth, malignant hematological systemic diseases, viral diseases, carcinomas, sarcomas, myelomas, melanomas, lymphomas, papillomas, degenerative diseases, allergic diseases, asthma, psoriasis and pain. More particularly, this invention relates to processes and compositions for treating these diseases by administering to a patient a pharmaceutically effective low dose amount of gamma interferon.
    Type: Grant
    Filed: April 18, 1990
    Date of Patent: September 8, 1992
    Assignee: Bioferon Bichemische Substanzen GmbH & Co.
    Inventors: Johann-Friedrich von Eichborn, Hans-Joachim Obert, Josef Brzoska
  • Method and agents for promoting wound healing
    Patent number: 5145676
    Abstract: The present invention relates to the treatment of wound healing dysfunction by the administration of one or more would healing modulators. The wound healing modulator may be selected from appropriate wound healing agents and binding partners, and particularly agents that enhance wound healing. The agent may comprise a cytokine, or mixture of cytokines that are also capable of binding to heparin, and inducing localized inflammation characterized by polymorphonuclear cell infiltration when administered subcutaneously. Particular agents comprise the inflammatory cytokines MIP-1, MIP-1.alpha., MIP-1.beta. and MIP-2. Diagnostic and therapeutic utilities are proposed, and pharmaceutical compositions are likewise set forth.
    Type: Grant
    Filed: February 7, 1991
    Date of Patent: September 8, 1992
    Assignee: The Rockefeller University
    Inventors: Thomas J. Fahey, III, Barbara A. Sherry, Anthony Cerami